Cargando…
BTB(BCL6) dimers as building blocks for reversible drug-induced protein oligomerization
Here, we characterize the BTB domain of the transcription factor BCL6 (BTB(BCL6)) as a small-molecule-controlled, reversible oligomerization switch, which oligomerizes upon BI-3802 treatment and de-oligomerizes upon addition of BI-3812. We show that the magnitude of oligomerization can be controlled...
Autores principales: | Nitsch, Lena, Jensen, Patrizia, Yoon, Hojong, Koeppel, Jonas, Burman, Shourya Sonkar Roy, Fischer, Eric Sebastian, Scholl, Claudia, Fröhling, Stefan, Słabicki, Mikołaj |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9046236/ https://www.ncbi.nlm.nih.gov/pubmed/35497498 http://dx.doi.org/10.1016/j.crmeth.2022.100193 |
Ejemplares similares
-
Small molecule-induced polymerization triggers degradation of BCL6
por: Słabicki, Mikołaj, et al.
Publicado: (2020) -
Backbone resonance assignment of the BCL6-BTB/POZ domain
por: Lin, Li-Ying, et al.
Publicado: (2017) -
Functionalization of the BCL6 BTB domain into a noncovalent crystallization chaperone
por: Zacharchenko, Thomas, et al.
Publicado: (2021) -
The human E3 ligase RNF185 is a regulator of the SARS-CoV-2 envelope protein
por: Zou, Charles, et al.
Publicado: (2023) -
The Ansamycin Antibiotic, Rifamycin SV, Inhibits BCL6 Transcriptional Repression and Forms a Complex with the BCL6-BTB/POZ Domain
por: Evans, Sian E., et al.
Publicado: (2014)